Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CervoMed Inc CRVO

Healthcare Biotechnology
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.


NDAQ:CRVO - Post by User

CervoMed Inc
<< Previous
 Bullboard Posts
User Avatar Image
(291)
•••
Post by whytestockson Dec 17, 2024 6:30pm
33 Views
Post# 36367158

Neutral Recommendation Issued On CRVO By H.C. Wainwright

Neutral Recommendation Issued On CRVO By H.C. Wainwright
JUST IN: $CRVO Neutral Recommendation Issued On CRVO By H.C. Wainwright2024-12-17 06:30:06 ET H.C. Wainwright analyst issues NEUTRAL recommendation for CRVO on December 17, 2024 11:10AM ET. The previous analyst recommendation was Buy. CRVO was trading at $2.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...CRVO - Neutral Recommendation Issued On CRVO By H.C. Wainwright

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities